Resalis Therapeutics
Resalis Therapeutics’ transformative metabolic disease approach targets MIR-22 which is a master regulator of multiple pathways underlying obesity and fatty liver disease.
The company is applying its understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable fat loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will with the most recent funding bring RES-010 into clinical trials.
http://resalistherapeutics.com
For more information, please contact:
Phone: +45 2270 5065